Please assess the completion status of the following clinical trial:

Trial Title: Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female or male of 50 to 85 years old with a care giver~* Mini Mental Status (MMS) test between 16 to 26 inclusive~* Clinical Dementia Rating (CDR) test inferior or equal to 1~* National Institute of Neurological and Communicative Disorders and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for an Alzheimer's disease~* Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test positive for dementia~Exclusion Criteria:~* patient already treated by medicines which could interfere with the study~* low level of vitamin B12 and folate which are considered as clinically relevant~* clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness....)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- EGb 761® (Tanakan®) (Type: EXPERIMENTAL): EGb 761® (Tanakan®)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).